Zykadia (ceritinib) / Novartis, BeiGene  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
ACTRN12616001187437: Molecular Profiling and Matched Targeted Therapy for Patients with Metastatic Melanoma (MatchMel)

Not yet recruiting
2
1000
 
Melanoma Institute Australia, Melanoma Institute Australia, National Health and Medical Research Council
Metastatic Melanoma
 
 
2019-001828-36: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Not yet recruiting
2
116
Europe
Brigatinib, Alecensa, Zykadia, Film-coated tablet, Capsule, hard, Alunbrig
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Takeda Pharmaceutical Company Ltd
Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC), Non-small cell lung cancer, Diseases [C] - Cancer [C04]
 
 
ALTA-2, NCT03535740: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Active, not recruiting
2
103
Europe, Canada, Japan, US, RoW
Brigatinib, AP26113
Ariad Pharmaceuticals, Takeda
ALK-positive Advanced NSCLC
09/20
06/24
NRG-LU003, NCT03737994: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Active, not recruiting
2
10
US
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Brigatinib, Alunbrig, AP 26113, AP-26113, AP26113, Biganib, Briganix, Trepmac, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ceritinib, LDK 378, LDK378, Zykadia, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Ensartinib, X-396, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, Lorviqua, PF-06463922, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy
National Cancer Institute (NCI), NRG Oncology
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
07/21
09/24
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Recruiting
2
6000
RoW
Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc.
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
12/26
12/27
NCT05489887: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting
2
76
Canada, US
Naxitamab, Danyelza, Ceritinib
Giselle Sholler, Y-mAbs
High-risk Neuroblastoma
09/26
09/33
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
IMPRESS-Norway, NCT04817956: Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
2
3000
Europe
Atezolizumab, Atezolizumab combined with bevacizumab, Phesgo (trastuzumab og pertuzumab), Alectinib, vismodegib, entrectinib, Vemurafenib and cobemitinib, Niraparib, Dostarlimab, Ceritinib
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna HF, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Cancer Metastatic
03/40
04/45

Download Options